Category: What’s new in MedTech

  • What’s new this week in US MedTech, 12 to 19 November 2026

    What’s new this week in US MedTech, 12 to 19 November 2026

    12 to 19 November 2026

    This is the second of our Thursday series on US MedTech. It was a week in which two tubeless insulin pumps were cleared within four days of each other, Medtronic moved to buy Contego after last week’s PMA, the Hugo robot was cleared for general surgery, and Roche received a De Novo authorization for automated mass spectrometry in the routine lab.

    1. Tandem and MiniMed both receive FDA clearance for tubeless insulin pumps with up to seven days of wear

    On 12 November Tandem Diabetes Care (Nasdaq: TNDM), based in San Diego, received 510(k) clearance for a new Tandem Mobi tubeless cartridge and infusion set, which converts the current Tandem Mobi pump into a tubeless device. The company describes it as the world’s first and only tubeless automated insulin delivery system with up to seven days of wear. Its 8-K notes that the tubeless infusion set is cleared for up to seven days of wear, while the cartridge is cleared for three days of use. The pump is now cleared for both tubeless and tubed infusion, and it uses Tandem’s Control-IQ+ technology. A full US commercial launch is planned for the first half of 2027, with tubeless supplies to be sold exclusively through the pharmacy for customers with pharmacy benefits. On 16 November MiniMed (Nasdaq: MMED), based in Northridge, California, announced FDA clearance of MiniMed Fit, the company’s first tubeless insulin pump. MiniMed describes it as the world’s first and only tubeless insulin pump with up to seven days of wear and no charging or cartridge changes in that period, with a 300 unit insulin capacity, app control and SmartGuard technology. The company says FDA clearance arrived several months ahead of expectations, and a phased US launch is now expected in spring 2027, earlier than the previously communicated summer 2027 timing. At commercial launch it will offer a choice of two sensors, Simplera Sync with up to seven days of wear and Instinct, made by Abbott, with up to 15 days of wear, and it will also be available through the pharmacy channel. It matters because two established pump companies are now entering the tubeless market in the same season, each with a seven day wear claim, and patients will have more than one new option to compare with today’s three day systems.

    Source: Tandem Diabetes Care 8-K and MiniMed

    2. Medtronic to acquire Contego Medical in a deal valued at $380 million

    On 16 November Medtronic (NYSE: MDT) announced its intent to acquire Contego Medical, the Raleigh company whose Neuroguard IEP Direct System received FDA PMA approval last week. The deal is valued at $380 million, with potential payments after the acquisition, and it builds on Medtronic’s exclusive US distribution agreement with Contego, first announced in January 2025. The planned acquisition includes Neuroguard IEP Direct, which Medtronic describes as the first and only transcarotid artery revascularization system with integrated embolic protection (TCAR-IEP) in addition to flow reversal, and Contego’s Excipio thrombectomy devices. Medtronic expects to complete the transaction in the third quarter of its fiscal year, subject to customary closing conditions. It matters because a distribution partnership has turned into an acquisition, and it follows immediately after a PMA that we covered in last week’s roundup.

    Source: Medtronic

    3. Medtronic’s Hugo robot is cleared for general surgery procedures in the US

    On 17 November Medtronic announced that the FDA has cleared the Hugo robotic-assisted surgery system for use in general surgery procedures. The 510(k) covers all upper abdominal general surgical procedures, including cholecystectomy, Roux-en-Y gastric bypass, ventral hernia and small bowel resection, as well as the lower abdominal procedures of inguinal hernia and appendectomy. Combined, Medtronic says these procedures account for about 3.5 million surgeries a year in the US, more than half of all soft tissue procedures performed in the country each year. The clearance expands Hugo’s US use beyond urology. Globally, the company says Hugo procedure growth is running at more than twice the robotic surgery market and is on track to surpass 50,000 procedures by the end of the Medtronic fiscal year. It matters because general surgery is where most of the soft tissue volume sits, and Hugo can now be used in those procedures in the US, not only in urology.

    Source: Medtronic

    4. Roche receives FDA De Novo authorization for the cobas pro i 601 mass spectrometry platform

    On 16 November Roche announced that the FDA has granted De Novo authorization for the cobas pro i 601 platform with the Ionify Gabapentin assay, part of its cobas Mass Spec solution. The company says the aim is to bring mass spectrometry, which has often been limited to specialized reference laboratories and manual workflows, into routine clinical laboratories through an automated, standardized process. The Gabapentin assay adds therapeutic drug monitoring to a US menu that already includes 25-Hydroxy Vitamin D total and steroid hormone assays such as estradiol and 17-Hydroxyprogesterone. Roche will use an FDA-authorized Predetermined Change Control Plan that covers the addition of up to 22 further Ionify assays on the same platform as the plan’s requirements are met. Those additional assays are not yet available. It matters because a De Novo plus a pre-agreed change plan can shorten the path for a whole menu, not only a single test.

    Source: Roche

    5. InspireMD’s CGuard Prime is approved for TCAR, and the first US commercial cases are done

    On 12 November Miami based InspireMD (Nasdaq: NSPR) announced FDA approval of a PMA supplement for the CGuard Prime TransCarotid Stent System for use in transcarotid artery revascularization procedures, when used with an embolic protection system specified in the labeling. The company later stated that the FDA approved the device on 9 November. The approval is supported by the CGUARDIANS II pivotal trial, a prospective, multicenter, single-arm US study of 50 patients at 11 sites, using CGuard Prime with the FDA-cleared ENROUTE Transcarotid Neuroprotection System in a high surgical risk population. At 30 days the study reported 100% acute device success, with no deaths, strokes, myocardial infarctions or stent thrombosis, and complete stent patency in evaluable subjects. InspireMD estimates that more than 35,000 TCAR procedures are performed in the US each year, and says the new indication doubles the CGuard Prime platform’s total addressable market. On 18 November the company announced the first US commercial TCAR procedures with the system, performed by Dr. Brett Almond in the greater Tampa Bay area, Dr. Gregory T. Clabeaux in Buffalo, New York, and Dr. Bradley R. Grimsley in Dallas, Texas. InspireMD is separately developing SwitchGuard, its own transcarotid neuroprotection system, which is investigational and not available for sale in the United States. It matters because the US carotid market now has another approved TCAR stent option, in the same week that Medtronic moved to buy Contego.

    Source: InspireMD (approval) and InspireMD (first commercial cases)

    6. Masimo receives 510(k) clearance for smartSedLine brain monitoring during anesthesia

    On 18 November Irvine based Masimo, a Danaher company, announced FDA 510(k) clearance for smartSedLine, a next-generation brain function monitoring solution intended to help clinicians assess changes in a patient’s response to anesthesia. The company says an enhanced Patient State Index algorithm responds faster during induction and is more stable when EEG power is low. The system is available as a new module and EEG sensor, and the module is plug-and-play with a compatible monitor such as Masimo Root. Masimo says this is its seventh FDA clearance in 2026. It matters because better information on depth of sedation, especially in high risk and older patients, is a practical need in the operating room, not only a new feature on a monitor.

    Source: Masimo

    7. FDA grants three Breakthrough Device designations, for a urine iNPH test, a spinal graft extender, and a syphilis fingerstick test

    On 18 November Haifa based Biostream announced that the FDA granted Breakthrough Device Designation on 12 November for its investigational urine test to aid the diagnosis of idiopathic normal pressure hydrocephalus in patients aged 60 and older, and to help distinguish it from Alzheimer’s disease and other neurodegenerative disorders. The test measures a panel of proteins and applies an algorithm to generate a probability score. It is not currently available for sale in the United States, and the company plans a prospective clinical validation study at US academic medical centers during 2027. On 17 November Lund based Moroxite announced a second Breakthrough Device Designation, this time for Xerafuse TOB, a tobramycin-eluting, resorbable bone graft extender intended for sacrolumbar spinal fusion in patients at increased risk of infection. The company’s lead product, Xerafuse BMP, received a Breakthrough designation in 2025. A Breakthrough designation is not FDA clearance or approval. Also on 17 November Halifax based MedMira (TSXV: MIR) announced Breakthrough Device Designation for its Multiplo Complete Syphilis (TP/nTP) Antibody Test, an instrument-free fingerstick test that simultaneously detects treponemal and non-treponemal antibodies from whole blood. MedMira also said that, following the designation, FDA’s Total Product Life Cycle Advisory Program team invited the company to apply for enrollment in its TAP Pilot. It matters because Breakthrough status can speed the conversation with the FDA, but it is still only a starting point, and none of these three tests or devices is cleared for US sale on the back of this week’s news.

    Source: PR Newswire (Biostream) and Moroxite and MedMira

    Gary’s take

    This week I kept coming back to how quickly a market can fill up once the first clearance arrives. On 12 November Tandem said it had the world’s first and only tubeless automated insulin delivery system with up to seven days of wear. Four days later MiniMed said much the same about MiniMed Fit, with a 300 unit reservoir and no cartridge change for up to seven days. Both plan to launch in 2027, and both will be going after today’s tubeless market as well as each other. The fine print matters here, because Tandem’s cartridge is cleared for three days even though the infusion set can stay on for seven. In carotid care the story continued from last week: Medtronic is now buying Contego, the company whose Neuroguard IEP Direct system we wrote about after its PMA, and InspireMD has already started its first commercial TCAR cases with CGuard Prime. That is what a competitive US market looks like, and it is generally good for physicians and patients, as long as we keep reading the labels and the payment rules with the same care we give to the press releases.

    When two clearances land in the same week and both claim to be first, what do you look at first, the wear time, the clinical data, or how the device will actually be paid for and supplied? You are always welcome to write to me directly, and you can find more of my articles, and book a short introductory call, at synergenmedtech.com.

    Sources note: all items were found through a public web scan of about 12 to 19 November 2026 and each was checked against the linked source. Amounts and dates are as reported by the companies or the cited media. The Medtronic agreement to acquire Contego Medical, the vVARDIS IPO and the Remedy Robotics Series B were covered in the 10 to 17 November funding and deals edition; Contego is included here because it follows last week’s PMA and is central to this week’s US carotid story. No new CMS payment decision in this window was added, and no additional US medtech IPO pricing was confirmed beyond the vVARDIS offering already covered on Tuesday.

    If you’d like to follow along, you can find us here:

    Website: synergenmedtech.com

    LinkedIn: linkedin.com/company/100981535

    YouTube: youtube.com/@synergenmedtech

    Download the full roundup as a PDF

  • What’s new this week in European MedTech, 11 to 18 November 2026

    What’s new this week in European MedTech, 11 to 18 November 2026

    11 to 18 November 2026

    Welcome to our second Wednesday look at European MedTech. This week the money went into heart monitoring, hospital sensors and handheld eye imaging, the EIC picked its latest Accelerator companies, two North American companies won MDR certificates for Europe, and the Parliament’s timetable for the MDR and IVDR revision slipped into January.

    1. Kardi Ai raises €5.3M Series A for wearable heart rhythm monitoring

    On 11 November Czech startup Kardi Ai raised €5.3 million in a Series A led by German health tech fund Callisto Health, with Česká spořitelna and Slovenská sporiteľňa (through Seed Starter), BrightCap Ventures, Purple Ventures, DEPO Ventures and Garage Angels. Its platform combines an ECG chest strap, a mobile app and AI analysis of the recordings, and it works with more than 70 hospitals in the Czech Republic and more than 6,000 users. Germany is the next priority, followed by planned entries in India, the UAE and Singapore. It matters because a Central European wearables company built a real hospital base at home before heading west.

    Source: Tech.eu

    2. Akara raises $5.5M for privacy friendly AI sensors in hospitals

    On 11 November Dublin based Akara, a Trinity College Dublin spin-out, raised $5.5 million led by Locke Health, bringing its total funding to $12.3 million. VTC Ventures, the EIC Fund, CommonKind and NovaVector Holdings joined existing investors ACT, Atlantic Bridge and Enterprise Ireland. Its wall mounted thermal sensors, with AI running on the device, show how clinical spaces are used without capturing detailed images of patients or staff, and the technology is already in hospitals in Ireland, the UK and the US. It matters because hospital capacity, and not only new therapies, is now attracting European investment.

    Source: Silicon Republic

    3. Siloton wins an £8.4M Innovate UK contract for handheld retinal imaging

    On 13 November it was reported that Bristol based Siloton has secured an £8.4 million ($11.1 million) two year contract from Innovate UK, through the Contracts for Innovation: Quantum Missions Primer initiative, to develop and clinically evaluate GiraffeOCT, a handheld OCT system built on a photonic chip. Trials of the in-clinic device will run with Sunderland Specialist Eye Hospital, and the York Health Economics Consortium will estimate the savings for the NHS, where nearly 623,000 patients were waiting for ophthalmology appointments at the end of July 2026. It matters because public money is helping move eye care out of the hospital and closer to home.

    Source: The Ophthalmologist

    4. The EIC picks 35 Accelerator companies, and DiaMonTech gets €2.5M for needle free glucose monitoring

    On 16 November the European Innovation Council announced 35 start-ups and SMEs selected from 453 full applications, with €84 million in proposed grants and 32 of them to be assessed for EIC Fund equity of up to €10 million each. Health names on the list include Surgecare (France, day 1 discharge decisions after abdominal surgery), EndoGene.Bio (France, uterine diseases), THEREMIA (France, clinical intelligence in CNS) and Sia Cellboxlab (Latvia, organ-on-chip). The same day Berlin based DiaMonTech said it is receiving €2.5 million from the EIC Accelerator to build a smartphone sized prototype, the D-Pocket, that measures glucose through the skin with mid-infrared light, in an 18 month project that began on 1 October. It matters because non-dilutive EU money is still one of the few ways to fund the riskiest device work in Europe.

    Source: European Innovation Council and EIC selected companies list and DiaMonTech

    5. Two North American companies win CE marking under the MDR

    On 17 November Dallas based Newton announced CE marking under the EU MDR for its Neurolens N3 eye alignment measurement system, issued by Intertek Medical Notified Body AB, and said it expects to reach its first European markets in 2027. On 16 November Calgary based MacuMira announced MDR CE marking, as a Class IIa device, for its microcurrent treatment for dry age-related macular degeneration, which is already used in more than 300 clinics, with more than 40,000 treatments delivered, in Canada, Australia and New Zealand. It matters because both products were helping patients elsewhere before Europe.

    Source: PR Newswire (Newton) and GlobeNewswire (MacuMira)

    6. Ceroflo opens a final Irish EIIS round of up to €5.5M, with trials starting in the US and Japan

    On 13 November Galway based Ceroflo launched its third and final EIIS round, of up to €5.5 million with a deadline of 30 November, to support clinical trials of its SubMax intracranial stent for intracranial atherosclerotic disease (ICAD). The company has treated two patients so far and says it is starting with the US and Japan. It was founded by stroke interventionists from Karolinska University Hospital in Sweden, Singapore and the Royal London Hospital. It matters because an Irish stent company with European founders is choosing to start its clinical path outside Europe.

    Source: Business Post (commercial report)

    7. MDR and IVDR revision: the indicative plenary date moves to January

    The European Parliament’s Legislative Observatory now lists 18 January 2027 as the indicative plenary date for the first reading of the MDR and IVDR simplification proposal, procedure 2025/0404(COD). Earlier this month it showed 14 December 2026. The lead Public Health committee (SANT), with Oliver Schenk as rapporteur, has still not voted, and the file reads “Awaiting committee decision”. Until Parliament and Council agree a final text and it is published, the current MDR and IVDR apply in full. It matters because every month of delay is another month under today’s rules.

    Source: European Parliament Legislative Observatory and Vigilo MedTech (status on 13 November)

    8. EUDAMED: the device registration deadline is 28 November

    Under the Commission’s EUDAMED transition timeline, devices whose first units were placed on the market before mandatory use began on 28 May 2026, including legacy devices, must be registered in the UDI/Devices module by 28 November 2026 if further units are still being placed on the market. Certificates issued under the MDR and IVDR must be registered by 28 May 2027. These dates follow Commission Decision (EU) 2025/2371. It matters because ten days from now, a device missing from EUDAMED becomes a compliance problem for every manufacturer still selling it in Europe.

    Source: European Commission (EUDAMED transition timeline) and EUDAPrep

    Gary’s take

    This week two companies from North America received MDR certificates, and both were already helping patients in other countries before Europe. I keep wondering what that tells us. My honest feeling is that the MDR has gone further than it needed to, and that much of the weight it adds ends up as paperwork in Brussels rather than as safer care. Many new products never reach European patients at all, or arrive years later, and an Irish stent company starting its trials in the US and Japan is one quiet example. I am still not sure whether this is good or bad, and I understand those who say that caution protects people. But I do believe European healthcare is paying for it, and that most people have no idea. The technology world talks about this every day, yet I am not convinced that doctors, health reformers, or even the people who run the MDR can see the treatments that never arrived. With the Parliament vote now pushed into January, it feels like a good moment to ask the question openly.

    When a good device reaches patients in Canada or the US before Europe, who in Europe should be asking why? You are always welcome to write to me directly, and you can find more of my articles, and book a short introductory call, at synergenmedtech.com.

    Sources note: all items were found through a public web scan of about 11 to 18 November 2026 and each was checked against the linked source. Amounts and dates are as reported by the companies or the cited media. The Ceroflo item comes from a commercial report in the Business Post. No new EU HTA joint clinical assessment for a medical device and no new MDR notified body designation were found in this window.

    If you’d like to follow along, you can find us here:

    Website: synergenmedtech.com

    LinkedIn: linkedin.com/company/100981535

    YouTube: youtube.com/@synergenmedtech

    Download the full roundup as a PDF

  • What’s new this week in Asian MedTech, 9 to 16 November 2026

    What’s new this week in Asian MedTech, 9 to 16 November 2026

    What's new this week in Asian MedTech

    9 to 16 November 2026

    A week with a strong Japanese and Korean flavour. Boston Medical Sciences raised a large Series B for AI colon cancer screening without laxatives, and Sysmex teamed up with London's Hologen to launch Saibogen, a Singapore based joint venture that reads more from routine blood counts. In Korea, Raywatt won a US FDA clearance and a Series B for its high speed coronary OCT, MedInTech closed a Series C for robotic endoscopy, and Lunit took its imaging AI into a Saudi government health system. Australia's Nanosonics widened its US clearance for endoscope cleaning, and in China, Osmunda raised money to build out medtech development and manufacturing infrastructure while Mingshi passed RMB 500 million in total funding for a visual cortex implant.

    1. Boston Medical Sciences raises ¥5.55 billion in a Series B for laxative free AI colon screening

    On 13 November Tokyo based Boston Medical Sciences, led by CEO Masaki Okamoto, announced a ¥5.55 billion Series B through a third party share allotment, co led by Japan Growth Capital Investment Corporation (managed by Nomura SPARX Investment), Global Brain and Beyond Next Ventures. The company was founded in April 2023 by physicians teaching and researching at Harvard Medical School and Massachusetts General Hospital, and is developing a "laxative free virtual endoscopy" that uses AI to clean the bowel virtually on CT images and help detect polyps. In Japan it was designated for priority review as software as a medical device and has completed its domestic clinical trial, and in the US it received FDA Breakthrough Device Designation in May 2026 and was accepted into the TAP pilot programme in June. The money goes to R&D, clinical evidence, Japanese and US regulatory work, preparation for launch in Japan and business development mainly in the US. It matters because the biggest barrier to colon cancer screening is the preparation, not the scan, and a Japanese team is tackling it for both home and US markets at the same time.

    Source: Boston Medical Sciences press release (PR TIMES)

    2. Sysmex and Hologen launch Saibogen, a Singapore based AI joint venture for "blood intelligence"

    On 9 November Kobe based Sysmex (President Iwane Matsui) and London based Hologen (CEO Roland Tegeder) announced Saibogen Pte. Ltd., a joint venture incorporated in Singapore on 2 November and led by CEO Leila Luheshi. Saibogen will apply Hologen's Large Medicine Models, generative AI trained on real world healthcare data, to the proprietary data produced by Sysmex hematology analyzers, which run about 3 billion tests a year, to extract new biological insight with no new instruments, reagents or samples. Its products will be delivered as software exclusively through Sysmex analyzers, and its first offerings will be for research use only. It matters because one of Japan's diagnostics leaders is betting that the next value in a mature test sits in the data it already collects, and it chose Singapore as the base to do it.

    Source: Sysmex

    3. Raywatt wins US FDA 510(k) clearance and a KRW 13 billion Series B for high speed coronary OCT

    On 12 November Korean imaging company Raywatt said its FASTER OCT imaging system (RV201) and four single use Chouette imaging catheters received FDA 510(k) clearance on 11 November US time, about nine months after filing. The system spins the catheter 400 times a second to image a coronary artery in about 0.5 seconds, works with saline as well as contrast, and is cleared as a Class II device for imaging coronary arteries of 2.0 to 3.5 mm in patients undergoing interventional procedures. The company says it is the first Korean developed intravascular OCT to win FDA clearance. On 16 November Raywatt added that it had raised a KRW 13 billion Series B from nine investors including InterVest, Life Asset Management and Hyundai Technology Investment, bringing total funding above KRW 23.5 billion, to fund US studies, CE MDR in 2027 and extension of the platform into cerebral vessels. CEO Jinyong Ha called the clearance proof that a Korean OCT has crossed the threshold of the US market. It matters because intravascular imaging is now a Class 1 guideline recommendation in complex stenting, and a new Asian competitor has entered a field long led by a few global players.

    Source: Financial News (News1) and Seoul Shinmun

    4. MedInTech closes a KRW 33.8 billion Series C to grow robotic endoscopy toward surgical robots

    On 16 November Korean startup MedInTech was reported to have closed a KRW 33.8 billion Series C, co led by existing investor Atinum Investment and new investor KB Investment. Founded in 2020, the company commercialised INTION S, a motorised AI endoscope system launched in Korea in June 2026, which cuts the weight of the control section from 610 g to 350 g and the force needed on the control wheels by up to 85%, with AI functions that help steer the scope and keep a lesion centred on screen. Before this round it had raised KRW 28 billion in total private funding up to its 2024 Series B and won large government R&D projects. The new money goes into a wider robotic endoscope line and development of a surgical robot. It matters because flexible endoscopy has been dominated by three Japanese companies for decades, and a Korean team is challenging them through motorisation and physical AI rather than optics alone.

    Source: theBell and Pharm Edaily

    5. Lunit will supply its imaging AI to Saudi Arabia's Ministry of National Guard Health Affairs

    On 9 November Seoul based Lunit announced that it will supply Lunit INSIGHT CXR for chest X ray and Lunit INSIGHT MMG for mammography to Saudi Arabia's Ministry of National Guard Health Affairs (MNGHA), a large government health system with major hospitals in Riyadh and Jeddah. The deployment will run through solutions by stc, the ICT arm of stc Group, as systems integrator, and the AI results will sit inside MNGHA's existing PACS workflow. It builds on Lunit's earlier Saudi work with SEHA Virtual Hospital and Dr. Sulaiman Al Habib Medical Group. CEO Brandon Suh said the aim is to widen access to AI powered cancer screening across the Middle East. It matters because Korean medical AI companies are increasingly winning national scale deals in the Gulf, often through a local integrator.

    Source: Lunit

    6. Nanosonics secures a second US FDA 510(k) clearance for its CORIS endoscope cleaner

    On 11 November Sydney based Nanosonics (ASX: NAN) announced that the FDA had granted a second 510(k) clearance for its CORIS System, an automated cleaner for the internal channels of flexible endoscopes, adding a number of high volume colonoscopes and gastroscopes to the devices it can reprocess. It builds on the earlier De Novo authorisation and a first 510(k) clearance. CEO and President Michael Kavanagh called it an important milestone and part of the planned US launch activities. It matters because channel cleaning is the critical first step in reprocessing reusable endoscopes, and every added scope model widens the market an Australian company can address in the US.

    Source: Kalkine (ASX announcement summary) and Market Index

    7. Osmunda raises an RMB 100 million Series D to build medtech development and manufacturing infrastructure

    On 13 November VCBeat reported that Guangzhou Osmunda Medical Device Technology (奥咨达), the medtech CRO and CXO platform founded in 2004 by regulatory expert Dr. Zhang Feng and Ms. Pan Wei, closed an RMB 100 million Series D, invested solely by the Lishui Green Valley Talent Osmunda fund. The money will build a headquarters manufacturing plant for contract production under China's MAH system, a provincial proof of concept centre and pilot workshop, a global AI platform for medtech innovation and its own medtech large language model, OSMED, and AI agents. The company says it has served more than 5,000 clients and helped obtain more than 2,500 NMPA registrations, 300 FDA registrations and 800 CE certificates. It matters because China's MAH system lets innovators register products without owning a factory, and service platforms that combine regulatory, development and production are becoming core infrastructure for Chinese startups going abroad.

    Source: VCBeat and PEdaily

    8. Mingshi passes RMB 500 million in total funding for a visual cortex prosthesis

    On 10 November Suzhou based Mingshi Naoji Technology (明视脑机), a start up about two years old, said it had closed pre-A and pre-A+ rounds, bringing total funding to more than RMB 500 million (about US$70 million). Round sizes were not disclosed. Shanghai Science and Technology Innovation Group and Minhang district's state owned fund co led the pre-A+ round, and Puhua Capital led the pre-A round. The company is building a visual prosthesis that bypasses the eye and optic nerve and stimulates the visual cortex directly, and says seven investigator initiated human experiments have caused no serious adverse events, with participants perceiving simple shapes. These are company claims, not peer reviewed results. The money is for a 1,024 channel system, registration testing and multicentre trials over the next one to two years. It matters because China's vision restoration BCI field now has well funded players at both the retina and the cortex.

    Source: NeuroTechGuide and VCBeat weekly funding roundup

    Gary's take

    I am writing this from China, and what strikes me this week is how much of Asia's medtech story is now about software and data on top of hardware. Sysmex is not selling a new analyser, it is reading more from the three billion blood counts it already runs. Boston Medical Sciences is using AI to remove the part of colon screening people hate most. MedInTech is motorising a Japanese dominated instrument so that AI can actually steer it. As someone who has spent years around cardiology, I was especially happy to see Raywatt get both its FDA clearance and its Series B in the same week, because that is exactly the combination a young device company needs to start a US journey properly. And from where I sit in China, Osmunda reminds me that the quiet infrastructure behind registration and manufacturing is what lets so many startups move fast. I fly to Japan at the end of the month for my fourth visit, and I am looking forward to hearing these stories first hand. My advice stays the same: in Asia, the winners pair real evidence with the right local partner, one market at a time.

    Which of these Asian stories matters most for your company, and is there a country or category you would like me to cover in more depth next week? You are always welcome to write to me directly, and you can find more of my articles, and book a short introductory call, at synergenmedtech.com.

    If you'd like to follow along, you can find us here:

    Website synergenmedtech.com
    LinkedIn linkedin.com/company/100981535
    YouTube youtube.com/@synergenmedtech

  • What’s new this week in Indian MedTech, 8 to 15 November 2026

    What’s new this week in Indian MedTech, 8 to 15 November 2026

    What’s new this week in Indian MedTech

    8 to 15 November 2026

    A week when policy and plain economics did most of the talking in Indian MedTech. The government extended the medical devices PLI scheme to 2035-36 with about Rs 2,700 crore still available, trade investigators recommended a five-year anti-dumping duty on examination gloves from Thailand and Malaysia, and Poly Medicure and Shalby told investors how they plan to grow and cut costs. On the startup side, Rymo Technologies brought in 1Crowd for affordable robotic rehabilitation and Froncort.AI won USD 2.3 million from Google.org, while cardiologists in Kerala asked for a review of the curbs on reprocessing single-use devices and doctors questioned the health claims of Deepinder Goyal’s Temple wearable.

    1. Government extends the medical devices PLI scheme to 2035-36, with about Rs 2,700 crore available
    On 10 November the Department of Pharmaceuticals invited fresh applications under the Production Linked Incentive Scheme for Promoting Domestic Manufacturing of Medical Devices (PLI-MD), now extended to 2035-36, with approximately Rs 2,700 crore of outlay to be used. Applicants get three years to set up facilities in four target segments: consumables, disposables and implants; critical components; high-end devices at a nascent stage of local manufacturing; and high-end devices that are only assembled in India today. Average tapering incentives are about 5%, 9%, 9% and 6% respectively. The minimum sales threshold to claim incentives has been dropped, the minimum investment requirement has been trimmed, and the application window will stay open for a long period. The government says the first phase led to domestic manufacturing of more than 60 high-end devices and components, including 1.5T MRI, CT scanners, LINAC and cath labs, with production worth over Rs 16,000 crore. The Indian Express noted that almost 80% of the original Rs 3,420 crore outlay had gone unused. It matters because the new rules openly target components and high-end equipment such as 3T MRI, PET-CT and ultrasound probes, which is exactly where India still imports most of what it uses.
    Source: Press Information Bureau and The Indian Express

    2. DGTR recommends a five-year anti-dumping duty on medical examination gloves from Thailand and Malaysia
    Medical Buyer reported on 10 November that the Directorate General of Trade Remedies, the investigation arm of the commerce ministry, has recommended a definitive anti-dumping duty on medical examination rubber gloves originating in or exported from Thailand and Malaysia. The proposed duty ranges from USD 442 to USD 565 per one lakh pieces, about Rs 42,650 to Rs 54,520, and would apply for five years. The recommendation is not automatically binding and now goes to the Ministry of Finance for a final decision. It matters because gloves are one of the highest volume consumables any hospital buys, so a notified duty would protect Indian makers but could raise landed costs for importers, distributors and hospital procurement teams.
    Source: Medical Buyer

    3. Rymo Technologies brings in 1Crowd to make robotic rehabilitation more affordable
    On 12 November early-stage fund 1Crowd said it has invested in Rymo Technologies, a Navi Mumbai company founded in 2020 by Chirag Shah, its CEO, and Abhishek Rai, which builds robotic and AI-assisted rehabilitation systems for patients recovering from neurological and orthopaedic conditions. The amount was not disclosed. Rymo’s portfolio spans robotic rehabilitation systems such as the flagship Mobi-L, balance trainers, XR and VR based therapy, and upcoming functional electrical stimulation devices. 1Crowd noted that imported robotic rehabilitation systems can cost Rs 1 to 1.5 crore and said Rymo’s solutions are about ten times more affordable. Co-Founder and Partner Natasha Kothari said healthcare and medtech make up about 20% of the 1Crowd portfolio. Rymo raised a seed round of about Rs 10 crore led by IAN Group in March 2026. It matters because rehabilitation is a huge, underserved need in India, and a device priced for smaller physiotherapy centres and mid-sized hospitals can reach patients that imported machines never will.
    Source: The Hindu BusinessLine and Inc Business

    4. Froncort.AI wins USD 2.3 million from Google.org for AI-based disease surveillance
    On 10 November Inc42 reported that Froncort.AI, founded in 2024 by physician-scientist Dr Ujjwal Rao, has secured USD 2.3 million (about Rs 21.5 crore) from Google.org, plus USD 200,000 in Google Cloud credits and pro bono support from Google’s AI specialists. It is one of 15 organisations selected globally for Google.org’s Impact Challenge: AI for Government Innovation. The money will build mAI-NETRA, a mobile version of its AI-NETRA platform, which combines government health data, satellite imagery and Google’s Earth AI models to point frontline workers to high-risk clusters. In a validation study with Maharashtra’s state TB programme, the company says teams found a similar number of confirmed pulmonary TB cases while screening two-thirds fewer people, and cost per confirmed case fell from about USD 29,000 to USD 10,000. The platform will extend to TB, leprosy, malaria, dengue, cholera and leptospirosis, and will be released as an open-source blueprint for governments. Froncort.AI also runs RegDoc, a regulatory submissions platform used by device makers and pharma companies. It matters because it shows how Indian AI teams are finding non-dilutive global money by solving public health problems at state scale.
    Source: Inc42

    5. Poly Medicure targets doubling revenue by FY30 and welcomes PLI 2.0
    On 14 November Medical Buyer, citing CNBC-TV18, reported that Poly Medicure Managing Director Himanshu Baid expects the company to double revenue by FY30, with 80% to 90% of growth from existing businesses and 10% to 15% from acquisitions, though no new acquisition is in the pipeline. Priorities are widening orthopaedics across trauma, joints and implants, and moving in cardiology towards interventional and eventually structural heart products. Baid said the extended PLI scheme covers most of what Poly Medicure makes and plans to launch in the next one to two years, and called component manufacturing one of its biggest opportunities. He also said Chinese renal products are being routed through FTA partner countries such as Malaysia at zero customs duty, and that an anti-dumping investigation has been initiated. In its Q2 FY27 call transcript filed on 11 November, the company reported consolidated H1 FY27 revenue of Rs 1,106 crore, up 31%. It matters because one of India’s largest device exporters is publicly tying its growth plan to PLI 2.0 and to trade remedies, which tells you where the industry’s lobbying energy is going.
    Source: Medical Buyer and Kalkine

    6. Shalby expects its new supply chain to cut implant manufacturing costs by a further 30% to 40%
    Medical Buyer reported on 13 November that Shalby Limited told investors in its Q2 FY27 call that a new MedTech supply chain should cut current implant manufacturing cost by a further 30% to 40%, after costs had already fallen by more than half since it acquired its US implant facility in 2021. Management expects the savings to start reaching the profit and loss account in Q4 FY27, with a full-quarter effect in Q1 FY28. MedTech EBITDA was Rs 36 lakh in Q2 FY27, up from Rs 16 lakh the quarter before, its fifth consecutive EBITDA-positive quarter, and MedTech inventory days fell to 784 from about 1,200 a year earlier. Shalby also cited approvals in Malaysia, Argentina and Nepal and said it expects an NPPA implant price revision around mid-November, which was management’s expectation rather than a confirmed decision. It matters because a hospital group that owns a US FDA implant line is trying to make the economics work by moving manufacturing cost, the same question every Indian orthopaedic maker faces against imported brands.
    Source: Medical Buyer

    7. Kerala cardiologists ask DGHS to review curbs on reprocessing single-use devices
    On 10 November Medical Buyer carried a PTI report that the Cardiological Society of India’s Kerala Chapter, at its annual conference, sought a review of DGHS restrictions on reprocessing medical devices labelled for single use. Chapter president Dr Asokan P K and organising chairman Dr Prathap Kumar N said the cost of complex angioplasty, especially procedures needing several specialised devices, often exceeds government insurance packages, and asked whether select catheters, guidewires and other equipment could be safely reprocessed under scientifically validated protocols. Dr Prathap Kumar stressed that patient safety must remain paramount, with validated sterilisation, functional testing and strict regulatory oversight. Medical Buyer followed up on 13 November with concerns over the impact of the ban on dialysis and cardiac care costs in Kerala. It matters because device makers, hospitals and regulators are now in an open debate about safety versus affordability, and the outcome will shape demand for disposables across India.
    Source: Medical Buyer (PTI) and Medical Buyer

    8. Doctors question claims of Deepinder Goyal’s Temple wearable and call for regulator review
    On 12 November Reuters, carried by The Hindu, reported that Temple, a head-worn wearable developed by Deepinder Goyal, co-founder of Eternal, the parent of Zomato, has drawn criticism from doctors over claims that its BrainFlow feature tracks blood flow to the brain in real time. The device weighs under 2 grams, sticks to the temple and costs Rs 85,000 (about USD 907). Hepatologist Dr Cyriac Philips, known as “TheLiverDoc”, called it “the biggest health scam”, and paediatrician and nephrologist Dr Sanjeev Bagai said it had “no formal approval or clearance”. Goyal says Temple is a fitness tracker and wellness device, not a medical one, while the company said some metrics would eventually need regulatory approval. Temple raised USD 54 million in February at a valuation of about USD 190 million, and Goyal said it has received orders from more than 62 countries since 1 November. It matters because the line between wellness gadget and medical device is now a public question in India, and CDSCO’s answer will matter to every wearable startup.
    Source: The Hindu (Reuters) and Medical Buyer

    Gary’s take
    I lived in India and have worked with Indian teams for many years, and this week felt very familiar to me. The headlines were about policy and money, but the real story is cost. PLI 2.0 finally gives makers three years to build and stops punishing them with sales thresholds, which is what the industry asked for, and Poly Medicure said so plainly. The glove duty, the Chinese renal products coming in through Malaysia and Shalby’s push to take 30% to 40% out of implant costs are all the same conversation: can India make good devices at a price Indian hospitals and patients can afford? Rymo’s rehabilitation robots at a tenth of the imported price are a lovely answer to that question. The Kerala cardiologists and the Temple debate remind me of the other half, which is trust. Affordability without safety, or bold claims without evidence, will not last. If you are building or selling in India, plan for both from day one.

    Which of these Indian stories matters most for your company, and is there a state, therapy area or company type you would like me to cover in more depth next week? You are always welcome to write to me directly, and you can find more of my articles, and book a short introductory call, at synergenmedtech.com.

    Sources note: all items were found through a public web scan of the week and each was checked against the linked original source. Poly Medicure’s half-year figures come from its Q2 FY27 earnings call held on 5 November, with the transcript filed on 11 November. The Shalby call date was not stated in the source.

    If you’d like to follow along, you can find us here:

    Website: synergenmedtech.com
    LinkedIn: linkedin.com/company/100981535
    YouTube: youtube.com/@synergenmedtech

  • What’s new this week in Israeli MedTech, 7 to 14 November 2026

    What’s new this week in Israeli MedTech, 7 to 14 November 2026

    What’s new this week in Israeli MedTech

    7 to 14 November 2026

    A week of deals, data and a hard lesson. Laguna Health found a US buyer that wants to grow its team in Tel Aviv, a Tokyo company agreed to acquire brain AI pioneer InnerEye, Clalit won Google.org backing for a voice assistant that works over a landline, Weizmann and the Hebrew University published a breast cancer blood test in Nature, BrainsWay and InMode reported their third quarters, Nanox added a reseller in Greece, and Art Medical reminded us how much rides on a single FDA decision.

    Deals and exits

    1. Elligint Health acquires Laguna Health and plans to double its Israeli team

    On 12 November Elligint Health, a New Jersey provider of care management and utilization management technology for US health plans, announced that it has acquired Laguna Health, a conversational AI company for health plan care teams. Ctech reported the deal at an estimated tens of millions of dollars, although the value was not disclosed. Laguna was founded in 2020 by Yoni Stein and Yael Peled-Adam, has raised about $30 million from investors including Pitango, LionBird, Arkin, HC9 and SemperVirens, and will stay in Israel as a wholly owned subsidiary and Elligint’s AI development arm, with Stein remaining CEO. Elligint plans to double the current team of about 20 people in Tel Aviv. It matters because a partnership announced only on 6 October turned into an acquisition within weeks, and the buyer is investing in the Israeli team rather than moving it.

    Source: Elligint Health and Ctech

    2. Tokyo’s Bio Search agrees to acquire Israeli brain AI company InnerEye

    On 9 November Bio Search, a Tokyo developer of biological sensing devices, medical equipment and data analysis platforms, announced a share exchange agreement to acquire 100% of InnerEye, the Herzliya company led by CEO Uri Antman that analyses EEG signals in real time. InnerEye was founded in 2014 by Prof. Amir Geva of Ben-Gurion University and Prof. Leon Deouell of the Hebrew University of Jerusalem. Closing depends on approvals from Israeli authorities and is planned between December 2026 and early January 2027, and Bio Search says it is working toward a NASDAQ listing in 2028. No value or exchange ratio was disclosed. It matters because a Japanese company is choosing Israeli academic science as the core of its global healthcare and brain tech platform.

    Source: Bio Search and Unite.AI

    Health systems and research

    3. Google.org gives Clalit $2 million for an AI voice assistant that works on any phone

    On 9 November Google.org awarded Clalit Health Services a two year, $2 million grant to build a conversational AI platform for its roughly five million members. The system will help patients schedule appointments, complete pre visit intake and symptom triage, and receive follow up guidance in multiple languages and regional dialects, and it will work over standard mobile phones and landlines as well as connected devices. Clalit plans a pilot before a national rollout and intends to release parts of the architecture as open source. It matters because Israel’s largest health provider is designing digital access for the patients who usually get left behind, those without a smartphone or a reliable internet connection.

    Source: The Jerusalem Post and Ctech

    4. Weizmann and Hebrew University blood test detects early breast cancer with 95% accuracy

    On 11 November researchers from the labs of Prof. Efrat Shema at the Weizmann Institute of Science and Prof. Guy Ron at the Hebrew University of Jerusalem published in Nature a blood test that reads the epigenetic tags on nucleosomes released into the bloodstream. Tested on samples from 77 breast cancer patients followed for at least five years at the Mayo Clinic in Florida and 30 healthy women, the AI models reached 95% accuracy in detecting early stage breast cancer and 81% accuracy in telling apart patients whose cancer returned from those whose cancer did not. The work was done with physicians at Kaplan Medical Center, and Sheba and Kaplan helped expand the blood sample set to 188 patients. It matters because it is still research, not a clinical test, but it shows strong performance regardless of breast density, which is exactly where mammography struggles.

    Source: Weizmann Institute of Science and Nature

    Company results and market access

    5. BrainsWay grows Q3 revenue 34% to $18.1 million

    On 10 November BrainsWay reported third quarter revenue of $18.1 million, up 34% from $13.5 million, with operating income up 107% to $2.6 million, net income of $2.2 million and $6.2 million of operating cash flow. The company shipped 130 Deep TMS systems in the quarter, up 44%, bringing its installed base to about 2,080 systems, and sold 54 OCD coils. It now expects full year 2026 results at the upper end of guidance. It matters because an Israeli neurostimulation company is showing that growing reimbursement coverage and a recurring revenue model can turn into real profitability.

    Source: GlobeNewswire (BrainsWay)

    6. InMode holds Q3 revenue at $92.1 million with record Asia sales

    On 11 November Yokneam based InMode reported third quarter GAAP revenue of $92.1 million, broadly in line with $93.2 million a year earlier, GAAP net income of $18.9 million and a cash position of $512.7 million. Revenue in Asia reached another quarterly record, consumables and service revenue fell 3% to $19.3 million, and the company reaffirmed full year revenue guidance of $365 million to $375 million after an initial launch of Morpheus8 Max. It matters because a mature Israeli aesthetics leader is finding its growth in Asia, while its US capital equipment revenue slipped to $42.7 million from $45.2 million.

    Source: PR Newswire (InMode)

    7. Nanox appoints Medworks to resell its HealthOST bone health AI in Greece

    On 13 November Nanox announced a non exclusive distribution agreement with Medworks for Nanox.AI in Greece, starting with HealthOST, its FDA cleared and CE marked AI software for bone health. The agreement builds on an existing deployment in Athens, and Medworks will provide local sales, technical support, applications and customer service. It matters because adding a local partner with service capability is often what turns a single reference site into a real national presence.

    Source: GlobeNewswire (Nanox)

    A hard lesson

    8. Art Medical turns to the court after an FDA setback

    On 10 November Ctech and TheMarker reported that Netanya based Art Medical, which has raised about $100 million since it was founded in 2008, filed for a temporary trustee and a stay of proceedings at the Central District Court. According to the filing, the FDA rejected a submission in October on the pathway for novel devices, after which investors stopped funding, leaving liabilities approaching $15 million. Its smART+ platform for managing nutrition in ventilated ICU patients bolds AMAR approval in Israel, a CE mark and UK registration, and the company employs 53 people. It matters because a product already used in leading Israeli hospitals could not survive without the US market, and that is a risk every founder should plan for early.

    Source: Ctech and TheMarker

    Gary’s take

    What touches me most this week is the contrast between Laguna and Art Medical. Laguna found a partner, earned its trust over a few weeks of working together and became the AI engine of a larger US group, while Art Medical had a product used in leading Israeli hospitals and still could not continue once one FDA decision went the wrong way. That is why I always tell founders to plan the US regulatory path, and the money behind it, long before they need it. I was also glad to see Bio Search choose InnerEye, because Japanese partners take time to decide and they value deep science, and to see Clalit build AI for the patient who only has a landline, which is what access should really mean.

    Which of these Israeli stories matters most for your company, and is there an area you would like me to cover in more depth next week? You are always welcome to write to me directly, and you can find more of my articles, and book a short introductory call, at synergenmedtech.com.

    Sources note: all items were found through a public web scan of the week and each was checked against the linked original source.

    If you’d like to follow along, you can find us here:

    Website: synergenmedtech.com
    LinkedIn: linkedin.com/company/100981535
    YouTube: youtube.com/@synergenmedtech

    Download the full roundup as a PDF

  • What’s new this week in MedTech, 7 to 13 November 2026

    What’s new this week in MedTech, 7 to 13 November 2026

    7 to 13 November 2026

    A week shaped by the heart and by the money behind new therapies. Abbott won approval on both sides of the Atlantic for a new defibrillation lead, Johnson & Johnson backed a prostate cancer ablation company, Oura moved from measuring health into delivering care, and AHA 2026 gave us a voice based heart failure study worth reading closely, while a large insulin pump correction and a new FDA guidance on emergency tests reminded us that safety and preparedness never stand still.

    1. Abbott wins FDA approval and CE mark for the UltiSynq defibrillation lead

    On 10 November Abbott announced FDA approval and CE marking for UltiSynq, a lead built for implantation in the left bundle branch area so that one lead can deliver both conduction system pacing and defibrillation with compatible ICD or CRT-D systems. In the ASCEND CSP trial, implantation succeeded in 202 of 205 patients, 86% achieved left bundle branch pacing or likely pacing, the three month major complication free rate was 97.5%, and defibrillation succeeded in all 120 patients who completed testing. It matters because physicians in the US and Europe implant about 150,000 and 140,000 ICDs a year respectively, and a purpose built lead removes the need for an extra pacing lead in many of those patients.

    Source: Cardiac Rhythm News and MedTech Dive

    2. Johnson & Johnson leads a financing round in Francis Medical for prostate cancer ablation

    On 10 November Francis Medical said Johnson & Johnson Innovation, JJDC, is leading a strategic financing that gives the company enough capital to reach its planned PMA submission for the management of clinically localized prostate cancer. The amount was not disclosed. Its Vanquish water vapor ablation system has had 510(k) clearance for prostate tissue ablation since November 2025, and the VAPOR 2 pivotal study is enrolling 235 patients at 26 US sites, with 91% of the first 110 showing no clinically significant MRI visible cancer in the treated area. It matters because a strategic investor is funding a company through the long PMA road from a tissue ablation tool to a cancer indication.

    Source: Francis Medical and MedTech Dive

    3. Oura agrees to acquire Counsel Health, moving from wearable insight to physician care

    On 10 November Oura announced a definitive agreement to acquire Counsel Health, the AI native, physician supervised care platform it has partnered with since May 2026, so that members can go from a change spotted by the ring to answers and care from a licensed physician inside the Oura App. Counsel physicians can diagnose, treat, order labs and prescribe when appropriate, and the deal is expected to close near the end of this year. Financial terms were not given in the announcement. It matters because a consumer wearable company is buying its way into clinical care, which changes how it will be viewed by regulators, payers and hospital partners.

    Source: Oura

    4. Cordio Medical reports DETECT-HF voice based heart failure results at AHA 2026

    On 9 November Cordio Medical presented DETECT-HF as Late Breaking Science at AHA 2026 in Chicago. In 563 patients at 46 sites, the HearO smartphone voice system detected 52 of 76 first heart failure events, a sensitivity of 68.4%, with the lower confidence bound of 58.0% just below the 60% target, while the unexplained alert rate of 2.65 per patient year met its goal of fewer than three, adherence to daily recordings was 85%, and events were flagged on average 24.1 days before clinical presentation. HearO is not cleared for sale in the US. It matters because it shows both the promise of hardware free remote monitoring and how carefully investors and regulators will read the endpoints.

    Source: JACC: Heart Failure and PR Newswire (Cordio Medical)

    5. Tandem Diabetes Care issues a correction for more than 80,900 Mobi insulin pumps

    MedTech Dive reported on 11 November that Tandem’s correction covers more than 80,900 Mobi pumps, mostly in the US, because a false occlusion alarm can suspend insulin delivery until the user acknowledges it. As of 29 October the company had received reports of 230 adverse events needing medical intervention or hospitalization, with no deaths reported, and users have been told they may keep using the pump but must respond to every occlusion alarm and keep a backup way to deliver insulin. It matters because a single mechanical issue at this scale touches patients, clinicians and the payers who fund connected diabetes devices.

    Source: MedTech Dive

    6. FDA cuts the analytical tests needed for emergency IVDs from 15 to five

    On 10 November FDA published final guidance on validating certain in vitro diagnostic tests for emerging pathogens during a Section 564 declared emergency, reducing the recommended analytical studies from 15 to five and supporting pre EUA and EUA submissions. It matters because diagnostic companies can now plan a much leaner validation package before the next outbreak, rather than building one under pressure once it starts.

    Source: Federal Register and RAPS

    7. Kardi Ai raises CZK 130M Series A to take AI ECG monitoring into Europe and Asia

    On 11 November the Czech company Kardi Ai announced a CZK 130 million Series A led by Callisto Health at a post round valuation of CZK 600 million, which it describes as the largest round to date among Czech medtech startups. It already operates in Czechia, Slovakia, Poland, Romania and Bulgaria, received an MD-15 import licence from India’s CDSCO in July 2026, holds a UAE Ministry of Health and Prevention registration, and is still working on approval in Singapore as its gateway to Southeast Asia. It matters because it is a clear example of a small European company planning its market access country by country, with registrations in hand before the money arrives.

    Source: Unite.AI

    8. Baird Medical enters South Korea through a partnership with ALLIS MED

    On 12 November Baird Medical (Nasdaq: BDMD) announced that ALLIS MED will act as its Korea License Holder, managing submissions to the Ministry of Food and Drug Safety, and will become the exclusive distributor of its microwave ablation products once certification is received. Thyroid tumor ablation in South Korea is mainly done with radiofrequency today, and Baird says it has entered Argentina, Egypt, Pakistan and Vietnam so far in 2026. It matters because using the local distributor as license holder is a practical way into a regulated Asian market, and it is a model I often discuss with companies planning their first steps in Asia.

    Source: GlobeNewswire (Baird Medical)

    Gary’s take

    What I take from this week is that the hard part is rarely the first clearance, it is everything that comes after it, and Francis Medical is a good example, because a 510(k) for a tool got them into the market while the real prize, a cancer indication, still needs a full PMA and a strategic partner patient enough to fund it. Cordio’s results are worth reading carefully too, because a study that meets one endpoint and narrowly misses another can still be a strong story, as long as the team explains it honestly to regulators and investors. And having spent more than 30 years working across Asia, I was glad to see the Baird and Kardi Ai stories, because they show what I keep telling founders: choose the right local partner, let them hold the licence where that makes sense, and build your registrations market by market before you scale.

    Which of these developments matters most for your company, and is there an area you would like me to cover in more depth next week? You are always welcome to write to me directly, and you can find more of my articles, and book a short introductory call, at synergenmedtech.com.

    If you’d like to follow along, you can find us here:

    Website: synergenmedtech.com
    LinkedIn: linkedin.com/company/100981535
    YouTube: youtube.com/@synergenmedtech


    Sources note: all items were found through a public web scan of the week and each was checked against the linked original source.

    Download the full roundup as a PDF

  • What’s new this week in US MedTech, 5 to 12 November 2026

    What’s new this week in US MedTech, 5 to 12 November 2026

    What's new this week in US MedTech, 5 to 12 November 2026

    5 to 12 November 2026

    This is the first of a new Thursday series on US MedTech. It was a week in which the FDA both opened doors and closed one: two De Novo authorizations and a carotid PMA, a 510(k) in wound care, a CMS reversal that will pay for a new breast imaging exam, two US financings, and a discussion paper on surgical robots that can work on their own or from a distance.

    1. Contego Medical wins FDA PMA for Neuroguard IEP Direct, a new TCAR-IEP approach

    On 10 November Raleigh based Contego Medical announced FDA premarket approval of the Neuroguard IEP Direct System and 510(k) clearance of the Neuroguard IEP Embolic Protection System. Used together, they provide dual neuroprotection through flow reversal and an integrated embolic protection filter via direct transcarotid access, which the company describes as a new approach category, TCAR-IEP, for carotid revascularization. In the PERFORMANCE III pivotal study, the 30-day stroke rate was 0% in the intention-to-treat population, with no myocardial infarctions, cranial nerve injuries, neurological deaths or stent thromboses. The primary endpoint, the 30-day rate of major adverse events, was 0.69% in the intention-to-treat population and 0% in the per-protocol population. The earlier Neuroguard IEP 3-in-1 system received FDA PMA approval in October 2024 for transfemoral and transradial carotid stenting and is commercially distributed by Medtronic. It matters because a PMA built on a 0% 30-day stroke rate gives physicians a transcarotid option that adds a filter to flow reversal.

    Source: PRWeb (Contego Medical)

    2. Virtuoso Surgical receives FDA De Novo authorization for its endoscopic robot

    On 10 November Nashville based Virtuoso Surgical announced that the FDA granted De Novo authorization for the Virtuoso Endoscopy System on 30 October 2026. It is the first device in a new FDA classification, electromechanical surgical systems for endoluminal surgical procedures. The system places two needle-sized robotic arms at the tip of a rigid endoscope, giving urologists two-handed dexterity for en bloc resection of bladder lesions through the urethra, so pathologists can receive a tissue sample that includes detrusor muscle. The system received FDA Breakthrough Device designation in September 2025, and Virtuoso plans a focused US launch at leading urology centers in 2027. It matters because a new device class has been created for a small robotic system designed to take a better diagnostic specimen, not only to remove a tumor.

    Source: Virtuoso Surgical

    3. Theraclion’s Sonovein wins FDA De Novo authorization for non-invasive vein treatment

    On 5 November French company Theraclion announced that the FDA granted De Novo marketing authorization for Sonovein on 4 November 2026. In the United States, Sonovein is intended for the coagulation of blood vessels in patients with superficial vein reflux in Great Saphenous Vein segments, using high intensity focused ultrasound from outside the body, without an incision or an intravascular catheter. The company says it is the first non-invasive HIFU platform to receive US marketing authorization for this use. Authorization was supported by the VEINRESET pivotal study of 70 patients at four US and European centers (NCT05926830), which met its primary endpoint with a 96.8% GSV occlusion rate at 12 months. No serious or unanticipated adverse events were reported, and only one mild adverse event was observed. A dedicated Category III CPT code has been active since 1 October 2026, which Theraclion describes as an initial step toward coverage and payment. The company has established a US subsidiary, Sonovein Inc., and says it is ready to begin commercial launch. It matters because a European company has opened the US vein market with a truly non-invasive approach, while payment pathways are still being built.

    Source: Theraclion

    4. FDA declines to approve Novocure’s Optune Mya for brain metastases from lung cancer

    On 9 November Novocure (Nasdaq: NVCR) said it had received a Not Approvable Letter from the FDA in response to its PMA application for Optune Mya, for the treatment of adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation. The FDA determined that uncertainty around the degree of clinical benefit prevented approval. The agency did not raise concerns related to the safety profile. Novocure plans to meet with the FDA to determine whether there are options that would support approval without additional clinical studies, and cautions that there can be no assurance those discussions will lead to an approval. The company’s US headquarters is in Portsmouth, New Hampshire. It matters because even a well known oncology device company can be turned back when the FDA is not convinced of the clinical benefit.

    Source: Novocure

    5. Luminoah raises $25M Series B, and EnVision Endoscopy closes an $11.5M Series A

    On 10 November Charlottesville based Luminoah announced a $25 million Series B financing led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, GV (Google Ventures), Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing investors. The round includes $20 million in new equity and $5 million in previously issued convertible notes that converted as part of the financing. The money will expand distribution of Luminoah Flow, the company’s FDA-cleared enteral feeding system (cleared in April 2026), increase manufacturing capacity, and continue development of Luminoah Intelligence, its clinician-facing data platform. The same day, Waltham based EnVision Endoscopy announced an oversubscribed $11.5 million Series A led by Puma Venture Capital, with participation from UTEC (University of Tokyo Edge Capital), existing investor Olympus Corporation of the Americas, and MassVentures. EnVision received FDA clearance for its SimpleStitch Suturing System in 2025, began a limited US market release in 2026, and has now completed its first 50 patient procedures. It matters because US investors are still funding companies that have already cleared the FDA and are now trying to get the technology into everyday use.

    Source: Luminoah and PR Newswire (EnVision Endoscopy)

    6. CMS reverses course and will pay for outpatient QTscan breast imaging from 2027

    On 9 November QT Imaging Holdings (Nasdaq: QTI) announced that CMS has established separately payable Medicare hospital outpatient payment for medically necessary, physician-ordered diagnostic QTscan examinations, effective 1 January 2027. The decision reverses CMS’s earlier proposal to classify QTscan examinations as nonpayable. Under the final 2027 Medicare Hospital Outpatient Prospective Payment System rule, CMS assigned QTscan’s dedicated CPT code 1079T to Ambulatory Payment Classification 5522, with status indicator S. The CPT code itself became effective on 1 October 2026. Routine screening of asymptomatic patients is not covered under current Medicare rules, and payment remains subject to medical necessity and documentation requirements. It matters because a clearance without payment often sits on the shelf, and this reversal gives hospitals a real reason to offer the exam.

    Source: QT Imaging

    7. Bechtel Medical receives 510(k) clearance for Wound VOX, combining negative pressure and topical oxygen

    On 10 November Phoenixville, Pennsylvania based Bechtel Medical announced 510(k) clearance from the FDA for Wound VOX. The company describes it as the first 510(k)-cleared system to combine negative pressure wound therapy and topical oxygen therapy on one platform, with three modes: continuous NPWT, intermittent NPWT, and intermittent NPWT with adjunctive topical oxygen. The company notes that topical oxygen therapy has faced reimbursement challenges, and plans a limited commercial release in December 2026. It matters because combining two therapies in one device may make treatment simpler for clinicians, but payment will still decide how widely it is used.

    Source: PR Newswire (Bechtel Medical)

    8. FDA asks for views on autonomous and remotely operated surgical robots

    On 6 November the FDA’s Center for Devices and Radiological Health released a discussion paper on evaluating benefit and risk in robotic medical devices with autonomous or remote teleoperation capabilities, including devices for surgery and for positioning or controlling instruments or imaging tools. The paper is for discussion only and does not represent draft or final guidance, and is not intended to propose or implement policy changes. Comments are requested under docket FDA-2026-N-13135 by 5 January 2027. It matters because the agency is inviting a conversation on telesurgery and autonomy before it writes the rules, and companies working in this area should take the chance to speak up.

    Source: FDA and American Hospital Association

    Gary’s take

    This week I kept coming back to a simple thought: getting through the FDA is only half the job. Contego, Virtuoso and Theraclion all earned important authorizations, and that is genuinely good news for patients. But a device that is cleared and not paid for often waits a long time before it reaches the people who need it. The QTscan story is a reminder of that, because CMS first proposed not to pay and then changed its mind, which is what will actually help hospitals offer the exam from January 2027. Theraclion already has a Category III CPT code, and Bechtel Medical itself notes that topical oxygen still faces reimbursement challenges. The Novocure decision shows the other side, that the FDA will still say no when it is not convinced of the clinical benefit, even for a company that already has products on the market. I would love to hear from people who have lived through this.

    Once you have the FDA letter in your hand, what has been the harder part, the regulatory path or getting paid? You are always welcome to write to me directly, and you can find more of my articles, and book a short introductory call, at synergenmedtech.com.


    Sources note: all items were found through a public web scan of about 5 to 12 November 2026 and each was checked against the linked source. Amounts and dates are as reported by the companies or the cited media. NIH SBIR awards announced in this window by Linshom Medical (a $3.5 million Phase 2B grant on 5 November) and Highland Instruments (a Phase IIB award announced on 9 November, with about $1.5 million in current year funding and about $1.4 million in recommended future support, subject to availability of funds and satisfactory progress) were covered in the 3 to 10 November funding and deals edition. Late breaking trial results from TCT were presented on 2 and 3 November, just before this window. No US medtech IPO pricing in this window was confirmed.

    Download the full roundup as a PDF

    If you’d like to follow along, you can find us here:

    Website: synergenmedtech.com

    LinkedIn: linkedin.com/company/100981535

    YouTube: youtube.com/@synergenmedtech

  • What’s new this week in European MedTech, 4 to 11 November 2026

    What’s new this week in European MedTech, 4 to 11 November 2026

    4 to 11 November 2026

    This is the first of a new Wednesday series on European MedTech. It was a week of steady, practical news rather than mega rounds: home dialysis and home stroke rehabilitation raised fresh money, sepsis and urology companies funded their next push across Europe, two European groups bought their way into new countries and new capabilities, two Korean companies cleared the MDR to enter Europe, and the European Parliament moved one step further on the MDR and IVDR revision.

    1. Nextkidney raises more than €20M Series C for its portable home dialysis device

    On 10 November Dutch medtech company Nextkidney said it had raised more than €20 million in a Series C round to complete development of the Neokidney, a portable hemodialysis device, and prepare it for market, with 3O Health among the investors and Dutch health insurers CZ, Menzis and Zilveren Kruis also involved. It is running a crowdfunding campaign through Invesdor for a further €3 million. The company reports 500 completed treatments across four medical centres in the Netherlands, Belgium and France, and this month starts a study in which patients perform 500 treatments independently outside the hospital. Subject to CE marking and FDA approval, it plans a first clinical launch at the end of 2027 and European home use in Q1 2028. It matters because European payers are putting their own money behind moving dialysis out of the hospital.

    Source: Dealroom News

    2. Bioliberty raises a €2.95M Series A extension to take stroke rehabilitation home

    On 6 November Edinburgh and Boston based Bioliberty announced a €2.95 million ($3.3 million) Series A extension, bringing its total funding to €12.07 million ($13.5 million). New backers are TGH Ventures (the investment arm of Tampa General Hospital), Ballad Ventures, Belfast based Whiterock and 25m Health. The company makes soft robotic upper limb rehabilitation technology, mainly for stroke survivors, and will use the money to extend it into the home, connect rehabilitation data across care settings and add AI decision support. It matters because rehabilitation after stroke is slowly moving from the clinic to the living room.

    Source: EU-Startups

    3. Efferon raises €4.3M to grow its sepsis blood purification devices

    On 10 November Efferon, which develops hemoadsorption devices that remove endotoxins and excess inflammatory mediators from the blood, said it had raised €4.3 million from existing private investors in the DACH region. Its devices are approved and used across Europe, are distributed in 46 countries, and have been used in more than 30,000 treatments. The money supports expansion of Efferon LPS and Efferon NEO in Europe, India and Latin America, its network of 21 distributors, regulatory work and clinical evidence. The company reported revenue above €1.1 million in 2025 and expects intensive care revenue of about €5 million in 2027. It matters because a small European critical care company is funding growth from loyal investors while it prepares for a full Series A.

    Source: Tech.eu

    4. Active Medical Xcellence closes a seven figure round for urological endoscopy

    On 9 November Jena based Active Medical Xcellence (AMX), a spinout of Active Fiber Systems, announced a seven figure growth round led by bm|t through the Thuringia Growth Equity Fund II, with MBG Thüringen, Sparkasse Jena Saale Holzland and a business angel joining. The money will expand sales and international reach for its MDR approved activeCut morcellator, used to treat benign prostatic obstruction, and develop its pipeline. It matters because regional public and savings bank capital in Germany is still backing small device makers that already carry an MDR certificate.

    Source: bm|t

    5. Two European deals: Rosti buys Alvi, and Eqwal buys the Preisler Group

    On 9 November Malmö based Rosti Group announced it has acquired Alvi Group, adding five sites in Leksvik (Norway), Tyresö (Sweden), Wrocław (Poland) and Suzhou (China) and about 400 colleagues. Alvi adds EUR 50 million to Rosti’s EUR 400 million in revenue, financial terms were not disclosed, and the acquisition took place on 2 November. On 6 November Eqwal Group announced the acquisition of the Preisler Group in Langen, Hesse, with 82 employees across technical orthopaedics, neurological therapy and assistive device distribution. It matters because European consolidation is happening quietly in the less glamorous parts of the chain, in contract manufacturing and in orthopaedic and rehabilitation care.

    Source: PR Newswire (Rosti Group) and Eqwal Group

    6. Two Korean companies win CE marking under the MDR

    On 10 November Seoul based RF Medical announced CE marking under the EU MDR for its Mi-BLATOR microwave ablation system, covering both the generator and the antennas, following the MDR CE marking of its THYBLATE-V2 thyroid RFA electrode in September 2026. The same day Beamworks said its breast ultrasound AI software CadAI-B Dx received CE marking under the EU MDR as a Class IIb device, after its earlier FDA 510(k) clearance. It matters because companies from outside Europe are still investing the time and money to get through MDR, and Europe remains a market they want.

    Source: PR Newswire (RF Medical) and Maeil Business (Beamworks)

    7. MDR and IVDR revision: Parliament’s IMCO committee adopts its opinion

    On 10 November the European Parliament’s Internal Market and Consumer Protection committee (IMCO) adopted its opinion on the MDR and IVDR revision, with all four negotiated compromise amendments winning a majority. The Budgets committee opinion is dated 5 November. The lead Public Health committee (SANT), with Oliver Schenk as rapporteur, has still not voted, the Legislative Observatory lists 14 December 2026 as an indicative plenary date, and health ministers meet on 8 December. Until a final text is adopted, which industry sources expect around Q2 to Q3 2027, the current MDR and IVDR apply in full and the transition deadlines of 31 December 2027, 2028 and 2029 are unchanged. It matters because every company planning a European launch is still working under today’s rules.

    Source: Pharma Deutschland and European Parliament Legislative Observatory

    8. MedTech Europe calls for repeal of the SCIP database

    On 4 November MedTech Europe and other associations published a joint statement asking EU policymakers to confirm the repeal of the SCIP database for substances of concern, as proposed by the European Commission under the Environmental Omnibus. They argue that after five years it duplicates information already required under REACH Article 33(1) and creates costly reporting, especially for SMEs and makers of complex products. It matters because the push to cut duplicated EU reporting now reaches well beyond the MDR itself.

    Source: MedTech Europe

    Gary’s take

    I want to put a gentle question mark over the MDR this week, because I am honestly not sure of the answer myself. My feeling is that the MDR has gone too far, and that a great deal of what it produces is Brussels bureaucracy rather than safer patients. Many good new products simply never reach the European market, and companies quietly launch in the US or Asia first, or not in Europe at all. Is that good or bad? Some will say it protects patients, and I respect that view. But when I look at hospitals around Europe, I believe European healthcare is paying a price, and most people are not aware of it. The technology world knows, but I am not sure doctors, healthcare reformers, or even the people who run the MDR see what is missing from their own clinics. This week’s news shows both sides, with companies like AMX, RF Medical and Beamworks getting through, and Brussels still debating how to simplify. I would love to hear what you see from where you sit.

    Has the MDR made European patients safer, or has it mainly kept good technology away from them? You are always welcome to write to me directly, and you can find more of my articles, and book a short introductory call, at synergenmedtech.com.

    If you’d like to follow along, you can find us here:

    Website: synergenmedtech.com

    LinkedIn: linkedin.com/company/100981535

    YouTube: youtube.com/@synergenmedtech

    Sources note: all items were found through a public web scan of about 4 to 11 November 2026 and each was checked against the linked source. Amounts and dates are as reported by the companies or the cited media. No new EIC Accelerator or Horizon results for medtech were published in this window, and no new MDR notified body designation was found.

    Download the full roundup as a PDF

  • What’s new this week in MedTech funding and deals, 3 to 10 November 2026

    What’s new this week in MedTech funding and deals, 3 to 10 November 2026

    3 to 10 November 2026

    This is the first of a new Tuesday series on MedTech funding and deals. It was a heavy week for capital: Boston Scientific and Blackstone agreed a large co-funding package for a heart pump, GE HealthCare led a major Series B for AI robotic imaging in the cath lab, Chinese investors put close to RMB 1 billion into brain computer interfaces, Rockwell Medical agreed to buy a global hemodialysis business, and two listed Chinese device groups took a large strategic stake that may lead to a merger. NIH grants also backed smaller device teams in respiratory monitoring and Parkinson’s neuromodulation.

    1. Boston Scientific and Blackstone Life Sciences agree up to $455M to co-fund the Vitalyst heart pump

    On 2 November, just as this week opened, Blackstone Life Sciences announced a collaboration under which it will provide up to $455 million to co-fund development of Boston Scientific’s VITALYST Temporary Percutaneous Transvalvular Circulatory Support System for acute myocardial infarction cardiogenic shock. It is the first time the two have co-funded a Boston Scientific product. Blackstone may receive regulatory and commercial milestone payments of up to about 2.5 times the capital it provides, plus royalties on net sales, and Boston Scientific has said it expects to start those payments in 2030. It matters because a capital heavy late stage device programme is being financed by sharing cost with a deep pocketed partner, rather than by a conventional equity round.

    Source: Blackstone and MedTech Dive

    2. Laza Medical raises up to $160M Series B led by GE HealthCare for AI robotic cath lab imaging

    On 4 November Laza Medical, a Shifamed portfolio company based in Los Gatos, California, announced a Series B structured financing of up to $160 million led by GE HealthCare, with returning investors Unorthodox Ventures, PA MedTech and AMED also participating. The money will advance its AI powered robotic imaging system for cardiac interventions. The Laza Medical System is under development and is not approved for commercial sale in any geography. It matters because a large imaging group is putting serious capital behind an AI robotics startup, and it was one of the week’s biggest device financings.

    Source: PR Newswire (Laza Medical)

    3. Rockwell Medical agrees to buy Vantive’s hemodialysis business for a $125M base price

    On 3 November Rockwell Medical (Nasdaq: RMTI) announced an Equity and Asset Purchase Agreement with Vantive Limited to acquire Vantive’s hemodialysis concentrates, HD machines including the AK-98, water treatment systems, and related consumables and technical services, together with Vantive’s one million square foot manufacturing campus in Medolla, Italy. The base purchase price is $125 million, financed through two $50 million term loans from Vantive and a $25 million convertible note, and Vantive may receive up to $45 million more in contingent consideration based on revenue and EBITDA milestones. The combined business is projected to generate annual revenue between $400 million and $450 million, and the deal is expected to close in mid-2027, subject to regulatory approvals and other closing conditions. Vantive’s dialyzer portfolio, including the Theranova dialyzer, is not included. It matters because a focused US dialysis supplier is using an acquisition, largely financed by the seller, to become a much larger global hemodialysis manufacturer.

    Source: Rockwell Medical and PR Newswire (Vantive)

    4. Zylox-Tonbridge and GL Capital invest about HK$1.482 billion in LifeTech Scientific

    On 6 November Zylox-Tonbridge Medical Technology (HKEX: 2190) and GL Capital announced they will jointly invest approximately HK$1.482 billion in LifeTech Scientific (HKEX: 1302) through GL Lighthouse Two Investment Limited, which will subscribe for newly issued shares representing about 16.7% of LifeTech’s enlarged share capital and become its largest single shareholder. Zylox-Tonbridge will hold a 60% stake in Lighthouse Two through an investment of about HK$889 million. In a related transaction, GL Capital will subscribe for 39.8 million newly issued Zylox-Tonbridge shares at HK$22 per share, about 10.8% of the enlarged share capital, at a 13.5% premium to the closing price on the announcement date. Zylox-Tonbridge also intends to pursue a potential merger with LifeTech, with the aim of building an integrated vascular and structural heart intervention platform in China. It matters because two listed Chinese device groups are using a large strategic stake, and a possible later merger, to put peripheral, neurovascular, aortic and structural heart products under one roof.

    Source: PR Newswire (Zylox-Tonbridge)

    5. Nanochap closes an RMB 500M Series C+ for its retinal vision implant

    On 3 November Hangzhou based Nanochap Electronics said it had closed an RMB 500 million Series C+ round led by Gaorong Ventures, with PICC Equity, Monolith, C&D Emerging Investment, Orient Jiafu, Danhe Capital and Hangzhou Industrial Investment Group joining, and existing shareholders including Legend Capital increasing their stakes. It is the company’s second round of 2026 after an RMB 300 million strategic round in May, bringing total funding to RMB 1 billion. Its E-BCI system pairs a 3 by 3 millimetre retinal implant with camera glasses, a registration trial is under way at three hospitals with three patients implanted so far, and the company aims for 30 implants in 2026 and to seek commercial approval in 2027. It matters because vision restoration is becoming its own funded category inside China’s fast growing BCI sector.

    Source: Inside BCI

    6. Active Technology raises an RMB 464M Angel+ round for invasive BCI

    On 4 November Shanghai Active Technology (主动科技), a Lingang Laboratory spinout founded in February 2026, announced an RMB 464 million (about $69.3 million) Angel+ round co led by Gaorong Ventures, SDIC Pilot Fund and Shanghai Science and Technology Venture Capital, with eight new investors and three existing shareholders joining. Together with its RMB 330 million angel round announced on 3 August, it has raised about RMB 800 million (about $119 million) in under three months, which Chinese media describe as a record for the angel stage in China’s BCI field. Its lead product, Tianshu, is a motor BCI aimed at movement and speech loss after stroke, spinal cord injury and ALS, and no human implant has yet been reported. It matters because Chinese investors are now paying later stage prices for very early implantable neurotech.

    Source: VCBeat and GS MedTech Funding Tracker

    7. Shanghai Yingjiexin closes an RMB 200M Series B for injection pens and autoinjectors

    On 5 November Shanghai Yingjiexin Medical Technology (Enjosim Medical) announced an RMB 200 million Series B (about $27.5 million) led by CICC Capital, with Zhuhai Technology Industry Group, CoStone Capital, Qiming Venture Partners and others joining, and existing backer Photon Venture Capital reinvesting. The company makes disposable prefilled pens, reusable injection pens and autoinjectors for biologics such as GLP-1 drugs, insulin and growth hormone, and says the money funds overseas registration and global production capacity. It matters because the GLP-1 boom is pulling Chinese drug delivery hardware makers into global supply chains, where the pharma partner, not the device maker, usually carries the filing.

    Source: MedDevice Startups and GS MedTech Funding Tracker

    8. OSSTEC closes $8M to take its cementless partial knee toward first US cases

    On 3 November London based OSSTEC, a 2021 spinout from Imperial College London, announced it had closed $8 million led by EMBRYO Ventures, with participation from Neovate Capital, New Wave Ventures, Oxford Technology Innovation Finance and Empirical Ventures. The capital will take ASCENT, its cementless fixed bearing partial knee system, and its CLARITY instrumentation through FDA clearance to first in human procedures in the United States, planned for the first half of 2027, and will also advance a 3D printed fixation platform. ASCENT and CLARITY are not cleared by the FDA and are not available for sale in the United States. It matters because European orthopedic innovation is still finding the capital to cross the Atlantic, one clearance and one first case at a time.

    Source: Business Wire (OSSTEC)

    9. NIH SBIR awards back respiratory monitoring and Parkinson’s neuromodulation

    On 5 November Baltimore based Linshom Medical announced a $3.5 million SBIR Phase 2B grant from the National Institutes of Health, National Heart, Lung and Blood Institute, to add wireless portable continuous respiratory monitoring and to run a multicenter clinical trial on the medical and economic benefits of earlier detection of respiratory decline. On 9 November Cambridge, Massachusetts based Highland Instruments announced a Phase IIB SBIR award from the National Institute of Neurological Disorders and Stroke for ESStim, its noninvasive neuromodulation platform for postural instability in Parkinson’s disease, with about $1.5 million in current year funding and about $1.4 million in recommended future support, for up to about $2.9 million in total, subject to availability of funds and satisfactory progress. ESStim has not been approved by the FDA for a specific clinical indication and is not in commercial distribution. It matters because non dilutive US grant money is still doing real work for smaller device teams, especially where the clinical path is long and a large commercial raise is not yet obvious.

    Source: Linshom Medical (EIN Presswire) and Highland Instruments

    Gary’s take

    What the money is telling us this week is that the biggest cheques are going to hard, capital heavy devices: a late stage heart pump, AI robotic imaging in the cath lab, and implantable brain interfaces in China, some of them still at a very early clinical stage. I also notice how deals are being structured, not only how large they are. Boston Scientific is sharing the cost of Vitalyst with Blackstone rather than carrying the whole programme on its own balance sheet, and Rockwell is buying a global dialysis business largely with seller financing. That tells me boards are looking for ways to move big assets without stretching the equity story too far. In China, Zylox-Tonbridge and LifeTech are using a large strategic stake, and talking about a possible merger, to build a broader vascular platform, which is a reminder that scale and a complete portfolio still matter there. The quieter NIH grants to Linshom and Highland are a useful counterpoint, because not every important programme needs a nine figure round, and non dilutive money remains a serious tool for smaller teams. My advice is to look as closely at the structure of a deal as at the headline number, because that is often where the real signal sits.

    Which of these funding stories matters most for your company, and is there a type of deal you would like me to cover in more depth next week? You are always welcome to write to me directly, and you can find more of my articles, and book a short introductory call, at synergenmedtech.com.

    If you’d like to follow along, you can find us here:

    Website: synergenmedtech.com

    LinkedIn: linkedin.com/company/100981535

    YouTube: youtube.com/@synergenmedtech

    Sources note: all items were found through a public web scan of about 3 to 10 November 2026 and each was checked against the linked source. Amounts and dates are as reported by the companies or the cited media. The Boston Scientific and Blackstone agreement was announced on 2 November, just as this window opened.

    Download the full roundup as a PDF

  • What’s new this week in Asian MedTech, 2 to 8 November 2026

    What’s new this week in Asian MedTech, 2 to 8 November 2026

    2 to 8 November 2026

    Another busy Asian week, led again by Chinese capital. Nanochap and Active Technology raised large rounds for implantable brain computer interfaces, Shanghai Yingjiexin closed a Series B for injection pens, and Rhino Health raised a B+ round to commercialise China’s first homegrown phaco vitrectomy system. Taiwan’s Ever Fortune.AI won a US FDA clearance for AI stroke triage, Japan saw a new NGS companion diagnostic approval and a Nihon Kohden sleep software clearance, and Korea added a portable wound therapy device and a government backed surgical training project.

    1. Nanochap closes an RMB 500M Series C+ for its retinal vision implant

    On 3 November Hangzhou based Nanochap Electronics said it had closed an RMB 500 million Series C+ round led by Gaorong Ventures, with PICC Equity, Monolith, C&D Emerging Investment, Orient Jiafu, Danhe Capital and Hangzhou Industrial Investment Group joining, and existing shareholders including Legend Capital increasing their stakes. It is the company’s second round of 2026 after an RMB 300 million strategic round in May, bringing total funding to RMB 1 billion. Its E-BCI system pairs a 3 by 3 millimetre retinal implant with camera glasses, a registration trial is under way at three hospitals with three patients implanted so far, and the company aims for 30 implants in 2026 and to seek commercial approval in 2027. It matters because vision restoration is becoming its own funded category inside China’s fast growing BCI sector.

    Source: Inside BCI

    2. Active Technology raises an RMB 464M Angel+ round for invasive BCI

    On 4 November Shanghai Active Technology (主动科技), a Lingang Laboratory spinout founded only in February 2026, announced an RMB 464 million Angel+ round co led by Gaorong Ventures, SDIC Pilot Fund and Shanghai Science and Technology Venture Capital, with eight new investors and three existing shareholders joining. Together with its RMB 330 million angel round announced on 3 August, it has raised about RMB 800 million in under three months, which Chinese media describe as a record for the angel stage in China’s BCI field. Its lead product, Tianshu, is a motor BCI aimed at movement and speech loss after stroke, spinal cord injury and ALS, and no human implant has yet been reported. It matters because Chinese investors are now paying later stage prices for very early implantable neurotech.

    Source: VCBeat and NeuroTechGuide

    3. Shanghai Yingjiexin closes an RMB 200M Series B for injection pens and autoinjectors

    On 5 November Shanghai Yingjiexin Medical Technology (Enjosim Medical) announced an RMB 200 million Series B (about $27.5 million) led by CICC Capital, with Zhuhai Technology Industry Group, CoStone Capital, Qiming Venture Partners and others joining, and existing backer Photon Venture Capital reinvesting. The company makes disposable prefilled pens, reusable injection pens and autoinjectors for biologics such as GLP-1 drugs, insulin and growth hormone, and says the money funds overseas registration and global production capacity. It matters because the GLP-1 boom is pulling Chinese drug delivery hardware makers into global supply chains, where the pharma partner, not the device maker, usually carries the filing.

    Source: MedDevice Startups and Guided Solutions funding tracker

    4. Rhino Health raises a B+ round to scale China’s first homegrown phaco vitrectomy system

    On 5 November VCBeat reported that Rhino Health, a developer of high end ophthalmic surgical equipment, closed a B+ round of nearly RMB 100 million led by In Capital, with Zhuhai Technology Industry Group participating. Its Genesis I and II combined phaco vitrectomy system was approved by NMPA on 15 December 2025 as the first product of its kind in China. Since commercial launch in June the company has signed contracts for more than 30 units and completed more than 10 installations, and founder Zhang Chi expects full year signings to approach 60 units. CE and FDA registration testing is complete. It matters because a domestic player is now competing directly with Alcon and Bausch + Lomb in one of ophthalmology’s most expensive equipment categories.

    Source: VCBeat

    5. Taiwan’s Ever Fortune.AI wins US FDA 510(k) clearance for AI large vessel occlusion detection

    On 2 November Taiwan’s Ever Fortune.AI (長佳智能) announced US FDA 510(k) clearance for its large vessel occlusion detection system, its 16th FDA clearance. The deep learning software analyses head CT angiography, flags suspected large vessel occlusions in the internal carotid artery and the M1 and M2 segments of the middle cerebral artery, and alerts the hospital PACS and RIS, with reported sensitivity of 96% and specificity of 94%. Combined with its existing brain haemorrhage and midline shift products, it now covers both haemorrhagic and ischaemic stroke, and the company holds 58 device licences worldwide, including 24 from Taiwan’s TFDA. It matters because a Taiwanese AI company is competing in US stroke triage, one of the most crowded imaging AI categories.

    Source: Commercial Times

    6. Thermo Fisher wins Japan’s first approval for the Oncomine Dx Express Test multi CDx system

    On 2 November Thermo Fisher Scientific Japan announced that on 30 October Japan’s MHLW approved the Oncomine Dx Express Test Multi CDx System, its first approval in Japan. The NGS based companion diagnostic identifies AKT1, PIK3CA or PTEN alterations in breast cancer for capivasertib, and NTRK1, NTRK2 and NTRK3 fusions in solid tumours for larotrectinib. Running on the Ion Torrent Genexus system, it automates the workflow from sample preparation to report and can deliver results in as little as 24 hours. Reimbursement procedures are still to follow. It matters because Japan is moving companion diagnostics toward faster, automated in hospital sequencing.

    Source: Thermo Fisher Scientific Japan

    7. Nihon Kohden’s Neurotronics wins FDA clearance for AI sleep analysis software

    On 3 November Neurotronics, a Nihon Kohden company, announced US FDA 510(k) clearance for its Sleep Analysis Module (SAM), with Nihon Kohden publishing the news on 6 November. The software only device uses the PPG signal already collected by a pulse oximeter to estimate total sleep time, so home sleep studies can measure apnea severity against estimated sleep time rather than total recording time, without extra sensors. It will first be integrated into Polysmith software for the NomadAir home sleep apnea test, and it is Neurotronics’ first FDA cleared AI/ML sleep algorithm. It matters because a Japanese monitoring group is adding value to home sleep testing through software rather than new hardware.

    Source: Nihon Kohden

    8. CGBio brings the portable single use Curasis Me wound therapy device to Korea

    On 3 November CGBio, the regenerative medicine affiliate of the Daewoong group, said its self developed Curasis Me portable single use negative pressure wound therapy system had received Korean MFDS approval on 22 September. It is smaller than the existing Curasis but applies the same negative pressure of minus 125 mmHg, and is approved for closed surgical incisions as well as chronic, acute and traumatic wounds, partial thickness burns, diabetic ulcers and pressure sores, so patients can continue treatment at home after discharge. Its predecessor Curasis2 is already sold in Thailand, the Philippines, Vietnam and China. It matters because wound care is following the wider shift of treatment from hospital to home.

    Source: ChosunBiz

    9. Medinnoa wins KRW 1 billion TIPS backing for AI and XR "digital clone" procedure training

    On 6 November Korean medical AI and XR company Medinnoa said it had been selected for the 2026 TIPS general track (third round), receiving KRW 1 billion in R&D support for an AI based digital cloning simulation solution for image guided interventional procedures. Its Medinnopia platform builds patient specific 3D models from CT and other images so physicians can rehearse procedures in XR, with realistic responses such as bleeding when a vessel is punctured. The funds go to digital clone accuracy, clinician usability testing and spatial tracking of patients and tools. It matters because Korea’s TIPS programme keeps seeding the training and planning tools that sit around devices, not only the devices themselves.

    Source: Money Today

    Gary’s take

    Two weeks in a row, the loudest story in Asia is Chinese money flowing into implantable brain computer interfaces. Nanochap and Active Technology together raised close to RMB 1 billion this week, only days after NeuroXess, and one of them has not yet implanted a single patient. I find that exciting and a little worrying at the same time, because capital can move faster than clinical evidence. The quieter stories teach me just as much: Rhino Health is proving a domestic device can win hospital contracts against the global giants, Ever Fortune.AI shows a Taiwanese team can earn its sixteenth FDA clearance in stroke, and Nihon Kohden and CGBio are both moving care toward the home. Having spent my career in sleep and stroke, it is good to see both fields so well represented. My advice to anyone planning Asia is the same as last week: the region rewards patience, local partners and real evidence, one country at a time.

    Which of these Asian stories matters most for your company, and is there a country or category you would like me to cover in more depth next week? You are always welcome to write to me directly, and you can find more of my articles, and book a short introductory call, at synergenmedtech.com.

    If you’d like to follow along, you can find us here:

    Website: synergenmedtech.com

    LinkedIn: linkedin.com/company/100981535

    YouTube: youtube.com/@synergenmedtech

    Sources note: all items were found through a public web scan of 2 to 8 November 2026 and each was checked against the linked source. Amounts and dates are as reported by the companies or the cited media.

    Download the full roundup as a PDF